Cabot falls after quarterly results weigh on Reinforcement Materials

What happened

Cabot (CBT) fell 4.9% on November 3, 2026, after the company reported quarterly results that showed strong Performance Chemicals performance but weaker Reinforcement Materials earnings. Trading volume was 2.0 times its 20-day average as the stock opened 7.0% below the previous close.

The wider market offered little comfort. The S&P 500 rose 0.4% on the day while the Basic Materials sector median fell 1.2%, making Cabot’s decline 3.8 percentage points worse than the sector median. Management said the results and segment mix drove the session’s move, and the size of the move was 3.5 times a typical daily move for this stock.

How big was the move

The session’s drop was sharper than recent patterns. Over the last five sessions the stock fell 2.7%, versus the S&P 500’s five-session decline of 2.0%. The stock’s market sensitivity, a beta of 0.71, indicates it tends to move less than the market, so the scale of Friday’s fall stood out.

Looking back, the stock had 15 sessions in the past five years with a decline of at least 4.9%. Twenty trading days after those sessions the median result was a gain of 2.0%, and 10 of the 15 were higher. That history suggests the stock has often recovered within a month after similar selloffs.

The technical picture

Technically the stock was trading below its short- and long-term averages: it was 3.1% below its 20-day moving average, 7.1% below its 50-day moving average and 9.5% below its 200-day moving average. The 50-day average is below the 200-day average, a sign of a weak longer-term trend.

Momentum indicators were muted. The Relative Strength Index (14 days) stood at 36, inside the neutral range between 30 and 70. The share price sat 23.8% below the 52-week high, had fallen 7.0% over one month and 14.8% over three months, and was up 6.7% over one year, leaving it 4.0 percentage points behind the S&P 500. Volatility was 22% annualized over 60 days, lower than 96% of its own readings over five years.

Fundamentals and valuation

For the four quarters through September 30, 2026, Cabot reported revenue of $3.74 billion, which grew 0.8% from a year earlier. Diluted earnings per share for the period were $4.05, a decline of 32.6% year over year. Gross margin narrowed to 21.8% from 25.3% a year earlier and operating margin fell to 13.0% from 16.7%.

The company generated a free-cash-flow margin of 5.7% and reported return on invested capital of 8.3%. On the balance sheet, net debt was 1.4 times EBITDA and the share count over one year decreased by 2.8%. Those figures point to modest cash generation and a balance sheet showing leverage in line with capital-intensive peers.

The stock traded at 17.8 times trailing earnings, a level higher than 71% of its own readings over the past five years, where the five-year median was 12.5 times earnings. Price to forward earnings stood at 10.3 times expected earnings and free-cash-flow yield was 5.6%. PromtFinance scores rank Cabot strong on Value (80) and Stability (83), positive on Quality (68), but weak on Growth (26) and Momentum (44).

Earnings and analyst expectations

Cabot reported last on November 2, 2026, with adjusted EPS of $1.61 for the quarter and diluted EPS of $1.25; fiscal 2026 adjusted EPS was $6.42 and diluted EPS was $4.02. The quarter’s adjusted EPS of $1.61 topped the Zacks Consensus estimate of $1.55. The company has beaten estimates in four consecutive quarters, with an average surprise over the last four reports of 6.0% above estimates.

Management said strong Performance Chemicals results partly offset weaker Reinforcement Materials earnings and noted the company generated $421 million in operating cash flow for the year while returning $243 million to shareholders via dividends and repurchases. Typical two-day reactions after recent reports saw the stock rise 0.4%.

Analysts following the stock place a consensus price target of $94.00, which is 30.6% above the closing price, based on 15 analysts. Forty-seven percent of those analysts rate the stock Buy or Strong Buy and the consensus rating is Buy. That gap between current price and the consensus target underscores differing views on whether near-term margin pressure will persist.

What to watch

• February 2, 2027: next scheduled earnings report.
• Fiscal 2026 adjusted EPS of $6.42 and diluted EPS of $4.02, with $421 million in operating cash flow for the year.
• Consensus price target $94.00, 30.6% above the closing price.
• Net debt of 1.4 times EBITDA and free-cash-flow margin of 5.7%.
• PromtFinance Value score 80 and Growth score 26.